Pegasus Mercantile Inc

Pegasus Mercantile, Inc. engages in providing advisory services, debt, and equity funding in the mid to late stages of a target company’s development or in technologies that are developed and validated but may be in the early stage of commercialization in the medical cannabis, hemp, CBD, and biotechnical markets. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2006-06-21. The firm is focused on hemp, cannabidiol (CBD), related, functional mushrooms, psilocybin plus other psychedelics, helping companies create sustainable products that elevate their personal health and wellbeing. The company is focused on the specific areas of pain, depression and mental illness. By investing in pioneering techniques, such as micro-dosing using organic compounds and synthetic molecules. The company is transforming the treatment of chronic pain, psychiatric ailments and depression by pioneering trials of fixed-dose drugs, combining psilocybin, ketamine, and MDMA, embracing the endless possibilities of micro-dosing. The company has 100% interest in Shanti Therapeutics Pty Ltd. (Shanti), which is focused on psychedelic MDMA-based drug development research.